ALK and non-small cell lung carcinoma: In crizotinib-treated (ALTA trial) and crizotinib-naïve (ALTA-1L trial) patients with ALK+ NSCLC, brigatinib has shown promising antitumor activity, including substantial activity against central nervous system (CNS) metastases (41, 64).